Pub. Date : 2011 Aug
PMID : 20514078
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. | Diltiazem | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 2 | In retrospective study, when coadministered with diltiazem, mean increments in dose-adjusted C(0D7), C(max) and AUC(0-12 h) for tacrolimus were larger in CYP3A5 expressers than in CYP3A5 nonexpressers (48.7 vs 3.7%, 31.7 vs 17.2% and 38.2 vs 18.5%, respectively). | Diltiazem | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 3 | In retrospective study, when coadministered with diltiazem, mean increments in dose-adjusted C(0D7), C(max) and AUC(0-12 h) for tacrolimus were larger in CYP3A5 expressers than in CYP3A5 nonexpressers (48.7 vs 3.7%, 31.7 vs 17.2% and 38.2 vs 18.5%, respectively). | Diltiazem | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 4 | For CYP3A5 expressers, an algorithm guided by CYP3A5 and diltiazem significantly reduced tacrolimus maintenance dosage (P=0.009) and improved the accuracy of tacrolimus initial dose, resulting in reduction in out-of-range C(0) after initial dose (P=0.002) and dose adjustments (P=0.004). | Diltiazem | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 5 | Our study results show that CYP3A5 genotype-guided tacrolimus-diltiazem combination is a promising therapy in renal transplant recipients in the early postoperative stage. | Diltiazem | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |